193 related articles for article (PubMed ID: 30333541)
1. Safety and Tolerability of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease.
Ma D; Wong W; Aviado J; Rodriguez C; Wu H
Am J Gastroenterol; 2019 Feb; 114(2):352-354. PubMed ID: 30333541
[TBL] [Abstract][Full Text] [Related]
2. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.
Van Assche G; Vermeire S; Noman M; Amant C; Weyts E; Vleminckx A; Vermeyen MJ; Rutgeerts P
J Crohns Colitis; 2010 Sep; 4(3):329-33. PubMed ID: 21122522
[TBL] [Abstract][Full Text] [Related]
3. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?
Bhat S; Sharma D; Doherty P; Tham TC; Caddy GR
Inflamm Bowel Dis; 2010 Nov; 16(11):1922-5. PubMed ID: 20848465
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Rapid vs Standard Infliximab Infusions in the Pediatric Population.
Rozette NA; Hellauer CM; McKee C; Vazifedan T; Gabriel CA; Dice JE; Yokois NU
Inflamm Bowel Dis; 2018 Aug; 24(9):2007-2014. PubMed ID: 29788416
[TBL] [Abstract][Full Text] [Related]
5. A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study.
Lee TW; Singh R; Fedorak RN
Aliment Pharmacol Ther; 2011 Jul; 34(2):181-7. PubMed ID: 21615434
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: A Canadian cohort study.
Ma C; Evaschesen CJ; Gracias G; Huang VW; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
Can J Gastroenterol Hepatol; 2015; 29(6):309-14. PubMed ID: 26069894
[TBL] [Abstract][Full Text] [Related]
7. Rapid Infliximab Infusion in Children: A Multicenter Retrospective Cohort Study.
Lev-Tzion R; Assa A; Yerushalmi B; Lahad A; Friedman M; Ledder O; Turner D
J Pediatr Gastroenterol Nutr; 2017 Nov; 65(5):e101-e103. PubMed ID: 29064928
[TBL] [Abstract][Full Text] [Related]
8. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease.
Qazi T; Shah B; El-Dib M; Farraye FA
Dig Dis Sci; 2016 Feb; 61(2):589-96. PubMed ID: 26441281
[TBL] [Abstract][Full Text] [Related]
9. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
[TBL] [Abstract][Full Text] [Related]
10. Premedication Use in Preventing Acute Infliximab Infusion Reactions in Patients with Inflammatory Bowel Disease: A Single Center Cohort Study.
Gold SL; Cohen-Mekelburg S; Schneider Y; Shen N; Faggen A; Rupert A; Scherl EJ; Bosworth B; Steinlauf A
Inflamm Bowel Dis; 2017 Oct; 23(10):1882-1889. PubMed ID: 28837521
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis: rapid infliximab infusions are safe.
Neef HC; Riebschleger MP; Adler J
Aliment Pharmacol Ther; 2013 Aug; 38(4):365-76. PubMed ID: 23815183
[TBL] [Abstract][Full Text] [Related]
12. Accelerated Infliximab Infusion: Safety, Factors Predicting Adverse Events, Patients' Satisfaction and Cost Analysis. A Cohort Study in IBD Patients.
Mazzuoli S; Tricarico D; Demma F; Furneri G; Guglielmi FW
PLoS One; 2016; 11(11):e0166443. PubMed ID: 27851772
[TBL] [Abstract][Full Text] [Related]
13. A nurse-led accelerated procedure for infliximab infusion is well tolerated and effective in patients with inflammatory bowel disease.
Michielan A; Martinato M; Favarin A; Zanotto V; Caccaro R; Caruso A; Sturniolo GC; D'Incà R
Dig Liver Dis; 2015 May; 47(5):372-7. PubMed ID: 25708258
[TBL] [Abstract][Full Text] [Related]
14. Does infliximab short infusion have a beneficial impact on the quality of life in patients with inflammatory bowel diseases? A single centre prospective evaluation.
Principi M; Losurdo G; La Fortezza RF; Lopolito P; Lovero R; Grillo S; Bringiotti R; Ierardi E; Di Leo A
J Gastrointestin Liver Dis; 2015 Jun; 24(2):165-70. PubMed ID: 26114175
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy.
Duron C; Goutte M; Pereira B; Bommelaer G; Buisson A
Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):705-11. PubMed ID: 25856689
[TBL] [Abstract][Full Text] [Related]
16. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability.
Bohra A; Rizvi QA; Keung CYY; Vasudevan A; van Langenberg DR
World J Gastroenterol; 2020 Sep; 26(36):5437-5449. PubMed ID: 33024395
[TBL] [Abstract][Full Text] [Related]
17. Safety of Accelerated Infliximab Infusions in Children With Inflammatory Bowel Disease: A Retrospective Cohort Study.
Jagt JZ; Galestin SE; Claesen J; Benninga MA; de Boer NKH; de Meij TGJ
J Pediatr Gastroenterol Nutr; 2023 Sep; 77(3):373-380. PubMed ID: 37319101
[TBL] [Abstract][Full Text] [Related]
18. Premedication with intravenous steroids does not influence the incidence of infusion reactions following infliximab infusions in pediatric inflammatory bowel disease patients-a case-control study.
van Wassenaer EA; Meester VL; Kindermann A; Koot BGP; Benninga MA; de Meij TGJ
Eur J Clin Pharmacol; 2019 Oct; 75(10):1445-1450. PubMed ID: 31332475
[TBL] [Abstract][Full Text] [Related]
19. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
Fréling E; Peyrin-Biroulet L; Poreaux C; Morali A; Waton J; Schmutz JL; Guéant JL; Barbaud A
Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1200-8. PubMed ID: 26181108
[TBL] [Abstract][Full Text] [Related]
20. Infliximab for very early-onset inflammatory bowel disease: A tertiary center experience in Japan.
Takeuchi I; Kaburaki Y; Arai K; Shimizu H; Hirano Y; Nagata S; Shimizu T
J Gastroenterol Hepatol; 2020 Apr; 35(4):593-600. PubMed ID: 31425641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
